Dansaert APO SRL
Dansaert APO reported total assets of 723,308 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Jul 2026).
The score of Dansaert APO shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +379 % Total assets +668 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Dansaert APO's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 173,021 € | ||||
| Equity | 113,040 € | ||||
| Cash | 202,585 € | ||||
| EBITDA | 191,001 € | ||||
| Total assets | 723,308 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Jul 2026
- Year ended 31 Dec 2024filed on 21 Jul 2025
- Year ended 31 Dec 2023filed on 13 Jul 2024
- Year ended 31 Dec 2022filed on 28 Jul 2023
- Year ended 31 Dec 2021filed on 28 Jul 2022
Dansaert APO's financial analysis
- Solvency15.6%sector median: 32.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Dansaert APO
Dansaert APO's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0707.924.311
- VAT number
- BE0707924311
- Peppol
- Registered · 0208:0707924311 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 08 Oct 2018
- Registered office
- 1000 Brussels
- Latest accounts
- 2025 · filed on 29 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Dansaert APO (SRL) has been based in Brussels since 2018, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 173,021 € and equity of 113,040 €; its revenue is not published. Its solvency stands at 15.6%, below the median of its sector (32.3%).
Companies similar to Dansaert APO
Companies in the same business, of comparable size and area, outside its group.
- Urservices Wholesale of pharmaceutical and medical goods Zottegem · balance sheet 570,973 €
- Deprophar Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 569,934 €
- Phytos Wholesale of pharmaceutical and medical goods Kortrijk · balance sheet 2,672 €
- CF Pharma Wholesale of pharmaceutical and medical goods Beaumont · balance sheet 469,314 €
- Paloma Curiosa Wholesale of pharmaceutical and medical goods Roeselare · balance sheet 710,783 €
- Euro Medical Wholesale of pharmaceutical and medical goods Burdinne · balance sheet 807,168 €
- DB Medic Wholesale of pharmaceutical and medical goods Bruges · balance sheet 579,690 €
- ALL Products Wholesale of pharmaceutical and medical goods Aalst · balance sheet 972,749 €
Frequently asked questions about Dansaert APO
What is the revenue of Dansaert APO?
Dansaert APO files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Dansaert APO?
In Belgium, the VAT number is the company number prefixed with BE: BE0707924311 for Dansaert APO, if the company is VAT-registered. Its company number (CBE) is 0707.924.311.
Where is the registered office of Dansaert APO?
According to the CBE register, the registered office of Dansaert APO is in 1000 Brussels.
What is the equity of Dansaert APO?
At the close of the 2025 financial year, the equity of Dansaert APO amounts to 113,040 €, a solvency of 15.6% of total assets.
Who manages Dansaert APO?
The register lists 4 active mandates at Dansaert APO. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Dansaert APO
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →